Sport Investors League
  • Politics
  • Stocks
  • Investing
  • Business

Sport Investors League

  • Politics
  • Stocks
  • Investing
  • Business
Investing

Top 5 Life Science ETFs in 2024

by admin November 20, 2024
November 20, 2024
Top 5 Life Science ETFs in 2024

Taking a position in a life science exchange-traded fund (ETF) provides exposure to a basket of stocks focused on the healthcare sector, while mitigating the risks of holding shares in a single company.

While ETFs provide diversification by their nature, fund managers often narrow down their offerings to follow a specific aspect of the market — for example, biotech or pharma. They also typically adjust the weight of ETF holdings to match movements in the life science industry in an effort to give investors the best possible returns.

Performance and asset under management (AUM) data was gathered on November 14, 2024, and the 10 life science ETFs listed by ETFdb.com were considered. Read on to learn more about the top-performing life science ETFs year-to-date.

1. SPDR Biotech ETF (ARCA:XBI)

Company Profile

Year-to-date gain: 16.8 percent
AUM: US$7.82 billion

Launched in 2006, the SPDR Biotech ETF tracks the performance of the S&P Biotechnology Select Industry Index, focusing exclusively on US stocks. The fund has an expense ratio of 0.35 percent, and its five year return comes in at 5.01 percent.

Of the fund’s 144 holdings, 76 percent are large and mid-cap companies. The fund’s top holdings include Incyte (NASDAQ:INCY), United Therapeutics (NASDAQ:UTHR) and Gilead Sciences (NASDAQ:GILD).

2. First Trust NYSE Arca Biotechnology Index Fund (ARCA:FBT)

Company Profile

Year-to-date gain: 13.1 percent
AUM: US$1.21 billion

The First Trust NYSE Arca Biotechnology Index Fund tracks the price and yield of an equity index called the Amex Biotechnology Index. Founded in 2006, the fund’s expense ratio is 0.56 percent. Its five year return comes in at 6.71 percent.

With 31 holdings, this fund is much smaller than the other ETFs on this list. It is primarily focused on large-cap US biotech companies, although it has exposure to some firms in Europe. Its top holdings include Exelixis (NASDAQ:EXEL), Intra-Cellular Therapies (NASDAQ:ITCI) and Incyte.

3. Vanguard Health Care Index Fund ETF (ARCA:VHT)

Company Profile

Year-to-date gain: 11.9 percent
AUM: US$17.95 billion

The Vanguard Health Care Index Fund ETF is a broad fund with healthcare firms from varied industries that came to market in 2004. It’s achieved returns of 11.07 percent over the last five years. The ETF’s expense ratio is very low at 0.1 percent.

At 414, this fund has the most holdings of the life science ETFs on this list, with more than 86 percent being large-cap companies predominantly in the United States. Its top holdings by weight include Eli Lilly (NYSE:LLY), UnitedHealth Group (NYSE:UNH) and AbbVie (NYSE:ABBV).

4. iShares US Medical Devices ETF (ARCA:IHI)

Company Profile

Year-to-date gain: 11.7 percent
AUM: US$4.9 billion

The iShares US Medical Devices ETF was launched in 2006 and, as the name suggests, focuses on medical device companies in the United States. The fund’s five-year return stands at 8.27 percent. This biotech ETF has an expense ratio of 0.4 percent.

This biotech fund is concentrated on large-cap companies, representing 89 percent of its holdings. Its top holdings by weight include Abbott Laboratories (NYSE:ABT), Intuitive Surgical (NASDAQ:ISRG) and Stryker Corporation (NYSE:SYK).

5. iShares US Healthcare ETF (ARCA:US)

Company Profile

Year-to-date gain: 11.7 percent
AUM: US$3.36 billion

The iShares US Healthcare ETF launched in 2000, making it the longest-running ETF on this list. EFTdb.com warns investors that ‘IYH probably doesn’t have much use for those constructing a long-term, buy-and-hold portfolio; this ETF is a more useful tool for those looking to establish a tactical tilt towards health care or for use in a sector rotation strategy.’

The fund has an expense ratio of 0.39 percent, and a five-year return rate of 11.12 percent. Of its 109 holdings, 94 percent are large-cap companies. Its top holdings by weight are Eli Lilly, UnitedHealth Group and Johnson & Johnson (NYSE:JNJ).

Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

0
FacebookTwitterGoogle +Pinterest
previous post
Dental supply stock surges on RFK’s anti-fluoride stance, activist involvement
next post
Indigenous-owned Mining Royalty Firm Targeting Canadian Resource Opportunities

Related Posts

Crypto Market Recap: White House Hosts Bitcoin Summit,...

March 9, 2025

Red Metal Resources Signs LOI to Acquire Mineral...

October 15, 2024

NexGen Signs First Uranium Contracts, Will Sell 5...

December 7, 2024

Top 9 Countries by Nickel Reserves (Updated 2024)

October 24, 2024

WOA receives R&D Tax Rebate

March 27, 2025

Spodumene Pegmatite Discovered at Agboville and Rubino

May 22, 2025

Randy Smallwood: Gold Price Strong, Now it’s Time...

March 25, 2025

Term Sheet for Hydrogen Supply and Offtake with...

January 6, 2025

Editor’s Picks: Gold Price Touches US$3,500 in Volatile...

April 27, 2025

Joe Cavatoni: Gold’s Next Price Catalyst After Record...

July 24, 2024

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent

    • Offense vs. Defense: How Geopolitical Tensions Shape Market Trends

      June 25, 2025
    • How to Use Fibonacci Retracements to Spot Key Levels

      June 25, 2025
    • Shifting Tides in the Stock Market: A New Era for Bulls?

      June 25, 2025
    • Experts gauge success of ‘bunker buster’ bombs dropped by US on Iran nuclear sites

      June 25, 2025
    • ‘I’m just a silly girl’: AOC fires back after Trump calls her ‘stupid’

      June 25, 2025

    Categories

    • Business (995)
    • Investing (2,462)
    • Politics (3,057)
    • Stocks (1,094)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: sportinvestorsleague.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 sportinvestorsleague.com | All Rights Reserved